 | • レポートコード：MRC2303F0145 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、248ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料は、2021年に546.4億ドルであった世界の肺疾患治療薬市場規模が、2022年に562.5億ドルになり、2027年まで年平均3.12%で成長して657.1億ドルに到達すると予想しています。本調査資料では、肺疾患治療薬の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疾患別（アレルギー性鼻炎、気管支喘息、COPD、嚢胞性線維症、その他）分析、薬物クラス別（抗コリン剤、抗ロイコトリエン、抗ヒスタミン剤、ベータ-2アゴニスト、その他）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめております。さらに、市場参入企業として、AstraZeneca plc、Bayer AG、Boehringer Ingelheim GmbH、Bristol-Myers Squibb Co.、F.Hoffmann-La Roche Ltd.、Gilead Sciences Inc.、GlaxoSmithKline plc、Mallinckrodt Pharmaceuticals、Merck & Co.、Novartis International AG、Pfizer Inc.、Sanofi S.A、Teva Pharmaceutical Industries Ltd.、Vertex Pharmaceuticals Incなどの情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の肺疾患治療薬市場規模：疾患別 - アレルギー性鼻炎における市場規模 - 気管支喘息における市場規模 - COPDにおける市場規模 - 嚢胞性線維症における市場規模 - その他疾患における市場規模 ・世界の肺疾患治療薬市場規模：薬物クラス別 - 抗コリン剤の市場規模 - 抗ロイコトリエンの市場規模 - 抗ヒスタミン剤の市場規模 - ベータ-2アゴニストの市場規模 - その他薬物クラスの市場規模 ・世界の肺疾患治療薬市場規模：地域別 - 南北アメリカの肺疾患治療薬市場規模 アメリカの肺疾患治療薬市場規模 カナダの肺疾患治療薬市場規模 ブラジルの肺疾患治療薬市場規模 ... - アジア太平洋の肺疾患治療薬市場規模 日本の肺疾患治療薬市場規模 中国の肺疾患治療薬市場規模 インドの肺疾患治療薬市場規模 韓国の肺疾患治療薬市場規模 台湾の肺疾患治療薬市場規模 ... -ヨーロッパ/中東/アフリカの肺疾患治療薬市場規模 イギリスの肺疾患治療薬市場規模 ドイツの肺疾患治療薬市場規模 フランスの肺疾患治療薬市場規模 ロシアの肺疾患治療薬市場規模 ... -その他地域の肺疾患治療薬市場規模 ・競争状況 ・企業情報 |
The Global Pulmonary Drugs Market size was estimated at USD 54.64 billion in 2021 and expected to reach USD 56.25 billion in 2022, and is projected to grow at a CAGR 3.12% to reach USD 65.71 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Pulmonary Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Indication, the market was studied across Allergic Rhinitis, Asthma, COPD (Chronic Obstructive Pulmonary Disease), Cystic Fibrosis, Others, and Pulmonary Arterial Hypertension.
Based on Drug Class, the market was studied across Anti-cholinergic Agents, Anti-leukotrienes, Antihistamines, Beta-2 Agonists, Combination Drugs, Monoclonal Antibodies, Oral and Inhaled Corticosteroids, and Others.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Pulmonary Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pulmonary Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Pulmonary Drugs Market, including AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., F.Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Mallinckrodt Pharmaceuticals, Merck & Co., Novartis International AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Inc.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Pulmonary Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pulmonary Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Pulmonary Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Pulmonary Drugs Market?
6. What is the market share of the leading vendors in the Global Pulmonary Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Pulmonary Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of chronic respiratory diseases, tobacco smoking
5.1.1.2. Drug innovation and availability of Biosimilars
5.1.1.3. Government and non-government initiatives
5.1.2. Restraints
5.1.2.1. Patent expiry of drugs
5.1.3. Opportunities
5.1.3.1. Increasing disposable income and rising investments in R&D
5.1.3.2. Increasing healthcare spending
5.1.3.3. Drug development through contract manufacturing
5.1.4. Challenges
5.1.4.1. Expensive clinical trials and commercialization of new drugs
5.2. Cumulative Impact of COVID-19
6. Pulmonary Drugs Market, by Indication
6.1. Introduction
6.2. Allergic Rhinitis
6.3. Asthma
6.4. COPD (Chronic Obstructive Pulmonary Disease)
6.5. Cystic Fibrosis
6.6. Others
6.7. Pulmonary Arterial Hypertension
7. Pulmonary Drugs Market, by Drug Class
7.1. Introduction
7.2. Anti-cholinergic Agents
7.3. Anti-leukotrienes
7.4. Antihistamines
7.5. Beta-2 Agonists
7.6. Combination Drugs
7.7. Monoclonal Antibodies
7.8. Oral and Inhaled Corticosteroids
7.9. Others
8. Americas Pulmonary Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Pulmonary Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Pulmonary Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. AstraZeneca plc
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Bayer AG
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Boehringer Ingelheim GmbH
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Bristol-Myers Squibb Co.
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. F.Hoffmann-La Roche Ltd.
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Gilead Sciences Inc.
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. GlaxoSmithKline plc
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Mallinckrodt Pharmaceuticals
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Merck & Co.
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Novartis International AG
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. Pfizer Inc.
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Sanofi S.A
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. Teva Pharmaceutical Industries Ltd.
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. Vertex Pharmaceuticals Inc
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing